Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8730
Title
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure
Author(s)
Date issued
2013
Citation
PLoS One. 2013 Sep 24;8(9):e75608.
Language
Inglés
Document type
journal article
Abstract
BACKGROUND: The development of HIV drug resistance and subsequent virological failure are often cited as potential disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of duration of infection at the time of initiation. METHODS: Patients enrolled in the UK Register of HIV seroconverters were followed-up from cART initiation to last HIV-RNA measurement. Through survival analysis we examined predictors of virologic failure (2HIV-RNA ≥400 c/l while on cART) including CD4 count and HIV duration at initiation. We also estimated the cumulative probabilities of failure and drug resistance (from the available HIV nucleotide sequences) for early initiators (cART within 12 months of seroconversion). RESULTS: Of 1075 starting cART at a median (IQR) CD4 count 272 (190,370) cells/mm(3) and HIV duration 3 (1,6) years, virological failure occurred in 163 (15%). Higher CD4 count at initiation, but not HIV infection duration at cART initiation, was independently associated with lower risk of failure (p=0.033 and 0.592 respectively). Among 230 patients initiating cART early, 97 (42%) discontinued it after a median of 7 months; cumulative probabilities of resistance and failure by 8 years were 7% (95% CI 4,11) and 19% (13,25), respectively. CONCLUSION: Although the rate of discontinuation of early cART in our cohort was high, the long-term rate of virological failure was low. Our data do not support early cART initiation being associated with increased risk of failure and drug resistance.
MESH
Anti-HIV Agents | Anti-Retroviral Agents | CD4 Lymphocyte Count | CD4-Positive T-Lymphocytes | Drug Resistance, Viral | Drug Therapy, Combination | Female | HIV | HIV Infections | HIV Seropositivity | Humans | Male | Risk | Treatment Failure
Online version
DOI
Collections